Pharmaceuticals

I-Mab Announces Partnership Agreement to Localize Manufacturing and Accelerate Commercialization of Innovative Biologics Drugs

SHANGHAI and GAITHERSBURG, Md., Jan. 28, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, announced the signing of a partnership agreement with the Hangzhou Qian...

2022-01-28 21:00 3241

Samsung Biologics reaches agreement with Biogen to acquire full ownership of Samsung Bioepis

* Agreement with Biogen to buyout Biogen's (50% -1 share) stake in Samsung Bioepis Joint Venture for up to USD$2.3 billion * Transaction projected to be accretive to earnings in 2022 and thereafter, fully capitalizing on the high growth potential of Samsung Bioepis * Expected to accelerate g...

2022-01-28 08:10 2824

Ractigen Therapeutics closes an additional $30 million in Series A+ funding to push development of its RNAa platform

NANTONG, China, Jan. 27, 2022 /PRNewswire/ -- Ractigen Therapeutics, a pioneer of the RNAa technology, today announced the closing of a Series A+ financing round totaling$30 million led by SDIC Venture Capital with participation from Eisai Co., Ltd., LC Ventures, CSSD Capital, and Xianghe Capital...

2022-01-27 22:10 2809

FDA Grants Breakthrough Therapy Designation for Dizal Pharmaceutical's DZD9008 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon20 Insertion

SHANGHAI, Jan. 27, 2022 /PRNewswire/ -- Dizal Pharmaceutical Co., Ltd. (SHEX:688192) ("Dizal"), today announced that the U.S. Food and Drug Administration ("FDA") has granted Breakthrough Therapy Designation toDZD9008 (Sunvozertinib) for the treatment of patients with locally advanced or metasta...

2022-01-27 21:15 4848

Brii Bio Appoints Karen D. Neuendorff as Chief People Officer and Head of Human Resources

DURHAM, N.C. and BEIJING, Jan. 27, 2022 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK) a multi-national company developing innovative therapies for diseases with significant unmet medical needs and large public healt...

2022-01-27 21:00 5794

Exyte Closes 2021 with Record Order Intake

- Order intake FY 2021 of over €8 billion, more than doubling YOY - Semiconductor and battery boom are main drivers for increased order intake - Outlook continues to be very positive STUTTGART, Germany, Jan. 27, 2022 /PRNewswire/ -- Exyte, a global leader in the design, engineering, and delivery ...

2022-01-27 20:53 4503

KLӦCKNER PENTAPLAST COMMITS TO rPET/PET CAPACITY EXPANSION FOR THE SUSTAINABLE HEALTHCARE AND FOOD PACKAGING MARKET IN NORTH AMERICA

LONDON, Jan. 27, 2022 /PRNewswire/ -- Klöckner Pentaplast (kp), a global leader in recycled content products and high-barrier protective packaging, has announced its intention to expand its post-consumer recycled content (PCR) PET capacity inNorth America with a significant investment to further ...

2022-01-27 20:00 2782

Adlai Nortye Announces Global License-out Agreement with Biotime for Several Products Including PD-L1 Inhibitor (AN4005) and Anti-hTNFR2 Antibody (AN3025)

NORTH BRUNSWICK, N.J. and HANGZHOU, China, Jan. 26, 2022 /PRNewswire/ -- Adlai Nortye Ltd. ("Adlai Nortye"), a clinical-stage biopharmaceutical company focused on the development of innovative cancer therapies, announced that it has entered into a Global License Agreement with Xiamen Biotime Biot...

2022-01-26 21:00 2382

Ascletis Announces IND Filing of Its Second FASN Inhibitor ASC60 for Advanced Solid Tumors Accepted by China NMPA

HANGZHOU, China and SHAOXING, China, Jan. 26, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: 1672) today announces that following the consultation with China National Medical Products Administration (NMPA), the Investigational New Drug (IND) application of its second fatty acid synthase (F...

2022-01-26 19:00 4379

Singapore Grants Approval for INDICAID COVID-19 Rapid Antigen Test as Consumer Self-test for SARS-CoV-2 Control

HONG KONG and SINGAPORE, Jan. 26, 2022 /PRNewswire/ -- PHASE Scientific International LTD  (PHASE Scientific), today announced that its INDICAID™ COVID-19 Rapid Antigen Test (INDICAID™) has received authorisation from the Health Sciences Authority ofSingapore, wh...

2022-01-26 17:18 3922

GenScript ProBio Initiates a CDMO Contract For Next-Generation CD47 Antibody with InnoBation Bio

SEOUL, South Korea, Jan. 26, 2022 /PRNewswire/ -- GenScript ProBio, a global biopharmaceutical contract development and manufacturing organization (CDMO), announced onJanuary 26th, 2022 that it entered into a contract with InnoBation Bio to develop and manufacture clinical trial sample substances...

2022-01-26 09:00 3665

Hope Medicine Announces US FDA Clearance for Phase II Clinical Trial of A First-in-class Monoclonal Antibody, HMI-115, in Androgen Alopecia

SHANGHAI, Jan. 25, 2022 /PRNewswire/ -- Hope Medicine Inc. ('HopeMed'), a clinical stage innovative biopharmaceutical company, has recently announced that U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for phase II study to evaluate HMI-115, a ...

2022-01-26 08:00 3541

SNIPR BIOME Announces U.S Food and Drug Administration grants Fast Track Designation for SNIPR001 for Prevention of Bloodstream Infections in Hematologic Cancer Patients

COPENHAGEN, Denmark, Jan. 25, 2022 /PRNewswire/ -- SNIPR BIOME ApS, a leading CRISPR and microbiome biotechnology company, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for SNIPR001. SNIPR001 is the company's first development candidate targeting E. coli i...

2022-01-25 22:42 2473

Neurophth Therapeutics' Treatment of Leber's Hereditary Optic Neuropathy Gene Therapy NR082 was Granted Orphan Drug Designation by EMA

WUHAN, China and SAN DIEGO, Jan. 25, 2022 /PRNewswire/ -- Neurophth Therapeutics, Inc., (hereinafter referred to as "Neurophth"), today announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) granted the orphan drug designation (ODD) for the Company's le...

2022-01-25 22:00 2544

Daewoong Pharmaceutical Released Positive Phase 3 Topline Results for New Antidiabetic Drug

SEOUL, South Korea, Jan. 25, 2022 /PRNewswire/ -- Daewoong Pharmaceutical (Daewoong) has confirmed promising phase 3 topline results that focuses on the therapeutic effects as an Enavogliflozin monotherapy and a combination therapy with Metformin.Daewoong's Enavogliflozin is an SGLT-2 inhibitor i...

2022-01-25 22:00 2281

KAZIA THERAPEUTICS TO PARTICIPATE IN EDISON GROUP'S GLOBAL HEALTHCARE 'OPEN HOUSE' VIRTUAL CONFERENCE

SYDNEY, Jan. 25, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that CEO, DrJames Garner, will be speaking at the Edison Group 'Open House' Event, to be held virtually from25-27 January 2022. Kazia ...

2022-01-25 21:00 4089

Senhwa's Pidnarulex Receives US FDA Fast Track Designation for the Treatment of Solid Tumors with BRCA1/2, PALB2 and other HR Gene Mutations

TAIPEI and SAN DIEGO, Jan. 25, 2022 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and novel coronaviruses, announced today that the US Food and Drug Administration (FDA) has granted Fast Track...

2022-01-25 20:00 2879

Sequanta selects Olink® Explore 3072 to analyze new cohort study in China

SHANGHAI, Jan. 25, 2022 /PRNewswire/ -- Olink Holding AB (publ) (Nasdaq: OLK) today announced that Sequanta Technologies, a leading multi-omics service provider based inChina, will use Olink® Explore 3072 to analyze the samples to serve a new large scale cohort study in China.  Since 2021, Sequa...

2022-01-25 19:36 1928

2022 Japan Prize Laureates Announced

TOKYO, Jan. 25, 2022 /PRNewswire/ -- The Japan Prize Foundation announced the winners of the 2022 Japan prize onJanuary 25. Prof. Katalin Kariko (Hungary/USA ) and Prof.Drew Weissman (USA) are co-winners of the Japan Prize in the field of "Materials and Production," and Prof.Christopher Field (USA...

2022-01-25 14:00 2501

Insilico Medicine Applauded by Frost & Sullivan for Enabling Rapid and Cost-Effective Drug Discovery and Development with Its Pharma.AI Platform

The Pharma.AI platform combining deep generative models (GAN), reinforcement learning (RL), transformers, and other modern machine learning techniques enables the identification of novel targets,generation of novel molecules  non-existent in the chemical space, and prediction of outcomes for clini...

2022-01-25 13:23 2485
1 ... 322323324325326327328 ... 348